A detailed history of Sg Americas Securities, LLC transactions in Castle Biosciences Inc stock. As of the latest transaction made, Sg Americas Securities, LLC holds 7,659 shares of CSTL stock, worth $215,217. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,659
Previous 26,989 71.62%
Holding current value
$215,217
Previous $588,000 62.93%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 03, 2024

SELL
$17.4 - $31.47 $336,342 - $608,315
-19,330 Reduced 71.62%
7,659 $218,000
Q2 2024

Jul 12, 2024

BUY
$18.84 - $24.94 $508,472 - $673,105
26,989 New
26,989 $588,000
Q3 2022

Oct 31, 2022

SELL
$22.51 - $34.32 $792,802 - $1.21 Million
-35,220 Reduced 89.44%
4,158 $108,000
Q2 2022

Jul 29, 2022

BUY
$16.0 - $45.99 $555,280 - $1.6 Million
34,705 Added 742.67%
39,378 $864,000
Q1 2022

Apr 29, 2022

SELL
$33.17 - $46.98 $117,886 - $166,966
-3,554 Reduced 43.2%
4,673 $210,000
Q4 2021

Feb 07, 2022

SELL
$39.06 - $67.58 $133,546 - $231,056
-3,419 Reduced 29.36%
8,227 $353,000
Q3 2021

Nov 01, 2021

BUY
$60.13 - $77.6 $548,024 - $707,246
9,114 Added 359.95%
11,646 $774,000
Q2 2021

Aug 12, 2021

SELL
$50.07 - $76.78 $3.12 Million - $4.79 Million
-62,344 Reduced 96.1%
2,532 $186,000
Q1 2021

May 13, 2021

BUY
$58.92 - $97.33 $241,513 - $398,955
4,099 Added 6.74%
64,876 $4.44 Million
Q4 2020

Feb 04, 2021

BUY
$43.6 - $73.05 $745,516 - $1.25 Million
17,099 Added 39.15%
60,777 $4.08 Million
Q3 2020

Nov 09, 2020

BUY
$38.47 - $52.03 $891,042 - $1.21 Million
23,162 Added 112.9%
43,678 $2.25 Million
Q2 2020

Jul 20, 2020

BUY
$27.28 - $43.01 $456,912 - $720,374
16,749 Added 444.62%
20,516 $773,000
Q1 2020

Apr 30, 2020

BUY
$23.08 - $35.53 $86,942 - $133,841
3,767 New
3,767 $112,000

Others Institutions Holding CSTL

About CASTLE BIOSCIENCES INC


  • Ticker CSTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 26,297,000
  • Market Cap $739M
  • Description
  • Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...
More about CSTL
Track This Portfolio

Track Sg Americas Securities, LLC Portfolio

Follow Sg Americas Securities, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sg Americas Securities, LLC with notifications on news.